Provectus, University of Miami agreement will advance photodynamic antimicrobial therapy
Click Here to Manage Email Alerts
Provectus Biopharmaceuticals announced an exclusive worldwide license agreement with the University of Miami for the university’s photodynamic antimicrobial therapy to treat bacterial, fungal and parasitic eye infections.
According to a company press release, the agreement allows Provectus to form a majority-owned startup company to develop and commercialize the photodynamic antimicrobial therapy (PDAT) medical device, which will used in combination with Provectus’ pharmaceutical-grade rose bengal sodium.
The creation of rose bengal PDAT was spearheaded by Jean-Marie Parel, IngETS-G, PhD, FARVO, director of the Ophthalmic Biophysics Center (OBC) at the university’s Bascom Palmer Eye Institute, who helped establish its merits for treatment-naïve and -resistant keratitis through extensive testing, including two international randomized clinical trials.
“The OBC’s innovation is sorely needed globally because infectious keratitis is the leading cause of corneal blindness in resourced and under-resourced countries,” Guillermo Amescua, MD, professor of clinical ophthalmology and medical director of the ocular microbiology laboratory at the Bascom Palmer Eye Institute, said in the release. “It is exciting to take something from the lab, apply it to clinical practice and see patients getting better.”
Ed Pershing, chairman of Provectus’ board of directors, added: “We look forward to working with Bascom Palmer and the OBC to reduce or eliminate the risk of blindness and impaired vision from eye infections for millions of people around the world through the promise of rose bengal sodium PDAT.”
Read more about
Click Here to Manage Email Alerts